NASDAQ · GILD
Gilead Sciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for GILD has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $2.17 | $2.35 | $1.93 | 6 |
| Dec 2026 | $2.05 | $2.22 | $1.77 | 5 |
| Mar 2027 | $2.17 | $2.25 | $2.09 | 2 |
| Jun 2027 | $2.30 | $2.35 | $2.24 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · The Motley Fool- RTTNews · Oct 29, 6:04 AM EDTGilead Sciences Q3 26 Earnings Conference Call At 4:30 PM ET(RTTNews) – Gilead Sciences Inc. (GILD) will host a conference call at 4:30 PM ET on October 29, 2026, to discuss Q3 26 earnings results.
- Zacks · Oct 28, 10:20 AM EDTAmgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.
- Zacks · Oct 27, 10:50 AM EDTGilead to Report Q3 Earnings: How Should You Play the Stock Now?Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant caution.
- Zacks · Oct 27, 10:15 AM EDTVertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.
- Zacks · Oct 27, 9:47 AM EDTWhat's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
- RTTNews · Oct 27, 9:36 AM EDTGilead Reaches Canadian Reimbursement Deal For Liver Disease Drug Lyvdelzi(RTTNews) – Gilead Sciences, Inc. (GILD) on Tuesday reported it concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on public reimbursement terms for Lyvdelzi (seladelpar), a treatment for primary biliary cholangitis (PBC).
- Zacks · Oct 26, 1:33 PM EDTBHC Q3 Earnings Preview: Here's What You Should KnowBausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.
- Zacks · Oct 26, 9:00 AM EDTTG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseTG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 26, 8:38 AM EDTBiogen Q3 Preview: Will Growth Products Drive an Earnings Beat?Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.
- Zacks · Oct 26, 8:15 AM EDTAhead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsLooking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
- Zacks · Oct 26, 7:55 AM EDTHow to Find Strong Medical Stocks Slated for Positive Earnings SurprisesThe Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
- The Motley Fool · Oct 25, 4:46 AM EDTAmgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?Amgen and Gilead pay forward dividend yields above 2%.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Gilead Sciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.